The purpose of this study is to assess the effectiveness of fedratinib in successive 28-day cycles to treat subjects with intermediate or high-risk primary myelofibrosis,
[rush.edu]
Methods: Eligibility criteria include age of at least 18 years, platelets >50,000/µl, ECOG PS 0–2, and a diagnosis of high- or intermediate-risk 2 primary MF, post-PV MF,
[ascopubs.org]
HR (95% CI) using IPSS were 2.3 (1.4–3.7) for high vs intermediate-2, 4.3 (2.2–8.5) for high vs intermediate-1, 6.6 (2.9–15.3) for high vs low, 2.9 (1.3–6.7) for intermediate
[nature.com]
